OverviewSuggest Edit

Bicycle Therapeutics is a biotechnology company based at the Babraham Research Campus in Cambridge, U.K. developing a novel technology for the creation of a new generation of biotherapeutics which combine the desirable features of small molecules and biopharmaceuticals. Bicycle technology is based on discoveries made at the MRC Laboratory of Molecular Biology in Cambridge by co-founders, Professor Christian Heinis and Sir Gregory Winter, which have been developed at the company into a robust technology platform under the leadership of Dr. John Tite (CSO). 
TypePublic
HQBabraham, GB
Websitebicycletherapeutics.com

Latest Updates

Employees (est.) (Sept 2019)67(+10%)
Job Openings4
Revenue (FY, 2018)$7.1 M(+247%)
Share Price (Jan 2020)$11.2

Key People/Management at Bicycle Therapeutics

Kevin Lee

Kevin Lee

CEO, Director
Kate Bingham

Kate Bingham

Director
Carolyn Ng

Carolyn Ng

Director
Lee Kalowski

Lee Kalowski

President and Chief Financial Officer
Nick Keen

Nick Keen

Chief Scientific Officer
Greg Winter

Greg Winter

Co-Founder and Director
Show more

Bicycle Therapeutics Office Locations

Bicycle Therapeutics has offices in Babraham and Lexington
Babraham, GB (HQ)
Meditrina Building, Babraham Research Campus
Lexington, US
4 Hartwell Pl
Show all (2)

Bicycle Therapeutics Financials and Metrics

Bicycle Therapeutics Revenue

Bicycle Therapeutics's revenue was reported to be $7.14 m in FY, 2018 which is a 246.4% increase from the previous period.
USD

Revenue (Q3, 2019)

614.0k

Net income (Q3, 2019)

(9.5m)

EBIT (Q3, 2019)

(10.3m)

Market capitalization (20-Jan-2020)

200.5m

Closing stock price (20-Jan-2020)

11.2

Cash (30-Sept-2019)

96.0m

EV

106.0m
Bicycle Therapeutics's current market capitalization is $200.5 m.
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Revenue

836.1k81.1k45.0k2.1m7.1m

Revenue growth, %

246%

General and administrative expense

6.4m8.1m

R&D expense

11.9m70.8m
Quarterly
USDQ2, 2019Q3, 2019

Revenue

1.5m614.0k

General and administrative expense

3.0m4.8m

R&D expense

6.5m6.1m

Operating expense total

9.5m10.9m
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Cash

2.3m451.3k5.4m6.5m67.7m63.4m

Accounts Receivable

5.0m

Prepaid Expenses

848.0k2.1m

Current Assets

2.7m989.3k6.2m8.3m71.5m76.8m
Quarterly
USDQ2, 2019Q3, 2019

Cash

108.5m96.0m

Accounts Receivable

160.0k46.0k

Prepaid Expenses

2.0m3.5m

Current Assets

120.5m110.3m
Annual
GBPFY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018

Net Income

(2.1m)(1.7m)(2.9m)(6.7m)(16.3m)(21.8m)

Depreciation and Amortization

332.0k712.0k

Accounts Payable

67.0k(169.0k)

Cash From Operating Activities

(1.4m)(26.1m)
Quarterly
USDQ2, 2019Q3, 2019

Net Income

(16.7m)(26.2m)

Depreciation and Amortization

443.0k686.0k

Accounts Payable

530.0k516.0k

Cash From Operating Activities

(12.8m)(23.7m)
USDY, 2019

EV/EBIT

-10.3 x

EV/CFO

-4.5 x

Revenue/Employee

9.2k

Financial Leverage

1.2 x
Show all financial metrics

Bicycle Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
BicycleRD Limited
Bicycle Therapeutics Inc
BicycleTx Limited

Bicycle Therapeutics Revenue Breakdown

Embed Graph

Bicycle Therapeutics revenue breakdown by business segment: 24.4% from Oxurion Agreement, 56.2% from Bioverativ Agreement and 19.4% from AstraZeneca Agreement

Bicycle Therapeutics Online and Social Media Presence

Embed Graph

Bicycle Therapeutics News and Updates

Bicycle Therapeutics shares soar 29% premarket on news of positive trial of DME treatment

Bicycle Therapeutics Ltd. shares soared 29% in premarket trade Monday, after the company announced positive results in a trial of a treatment for diabetic macular edema, or DME, a disease that causes damage in the blood vessels of the retina that can harm vision. The company said the Phase 1 trial …

Bicycle Therapeutics shares slide 10.7% in trading debut

Bicycle Therapeutics shares slide 10.7% in trading debut

Bicycle Therapeutics raises $60.2 million in IPO, Ideaya Biosciences raises $50 million

Bicycle Therapeutics plc priced its initial public offering late Wednesday at $14 per American Depositary Share, selling 4.3 million shares to raise $60.2 million. The stock will start trading later Thursday on Nasdaq, under the ticker symbol "BCYC." Separately, Ideaya Biosciences priced its IPo at…

Bicycle Therapeutics Blogs

Bicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401

Cancer Research UK to fund exploratory development of BT7401 through a Phase IIa clinical study LONDON & CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Jan. 7, 2020-- Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics ba…

Bicycle Therapeutics to Present at the Piper Jaffray 31st Annual Healthcare Conference

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Nov. 26, 2019-- Bicycle Therapeutics plc (NASDAQ:BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle® ) technology, today announced that manageme…

Bicycle Therapeutics to Present at the Jefferies 2019 London Healthcare Conference

CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Nov. 14, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC), a clinical-stage biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide ( Bicycle ® ) technology, today announced that

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT5528 in Patients with Advanced Solid Tumors

- BT5528 targets EphA2, an antigen believed to be overexpressed in tumor types with high unmet need and a target for which antibody-based approaches have been unsuccessful to date - Phase I dose escalation has commenced in the U.S and will be conducted at sites in both the U.S.

Bicycle Therapeutics Reports Third Quarter 2019 Financial Results and Corporate Update

- BT7480 selected as lead immuno-oncology candidate to advance into IND-enabling studies - Preclinical data on Bicycle® tumor-targeted immune cell agonists to be presented at SITC Annual Meeting on November 9, 2019 - Cash was $96.0 million at September 30, 2019 , which excludes $6.0 million UK R&amp…

Bicycle Therapeutics to Present New Preclinical Data on BT7480, a Novel, Fully Synthetic Bicycle® Tumor-targeted Immune Cell Agonist, at the Society for Immunotherapy of Cancer’s 2019 Annual Meeting

- BT7480 has been selected as the Company’s lead immuno-oncology candidate to advance into IND-enabling studies CAMBRIDGE, England & BOSTON --(BUSINESS WIRE)--Nov. 5, 2019-- Bicycle Therapeutics plc (NASDAQ: BCYC) a clinical-stage biotechnology company pioneering a new and differentiated class o…
Show more

Bicycle Therapeutics Frequently Asked Questions

  • Who are Bicycle Therapeutics key executives?

    Bicycle Therapeutics's key executives are Kevin Lee, Kate Bingham and Carolyn Ng.

  • How many employees does Bicycle Therapeutics have?

    Bicycle Therapeutics has 67 employees.

  • What is Bicycle Therapeutics revenue?

    Latest Bicycle Therapeutics annual revenue is $7.1 m.

  • What is Bicycle Therapeutics revenue per employee?

    Latest Bicycle Therapeutics revenue per employee is $106.5 k.

  • Who are Bicycle Therapeutics competitors?

    Competitors of Bicycle Therapeutics include Pandion Therapeutics, ImCheck Therapeutics and NeuralStem.

  • Where is Bicycle Therapeutics headquarters?

    Bicycle Therapeutics headquarters is located at Meditrina Building, Babraham Research Campus, Babraham.

  • Where are Bicycle Therapeutics offices?

    Bicycle Therapeutics has offices in Babraham and Lexington.

  • How many offices does Bicycle Therapeutics have?

    Bicycle Therapeutics has 2 offices.